CN100435783C - Orally administered composition containing fat soluble ingredient of red sage root - Google Patents
Orally administered composition containing fat soluble ingredient of red sage root Download PDFInfo
- Publication number
- CN100435783C CN100435783C CNB2005100364831A CN200510036483A CN100435783C CN 100435783 C CN100435783 C CN 100435783C CN B2005100364831 A CNB2005100364831 A CN B2005100364831A CN 200510036483 A CN200510036483 A CN 200510036483A CN 100435783 C CN100435783 C CN 100435783C
- Authority
- CN
- China
- Prior art keywords
- oil
- red sage
- emulsifying agent
- fat soluble
- orally administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to an orally administered composition containing fat soluble ingredients of red sage roots, which belongs to the field of pharmacy. The composition is made of the following percentage weight of raw material: 0.3% to 3% of fat soluble ingredients of red sage roots, 20% to 70% of oil, 25% to 75% of an emulsifying agent, and 0 to 20% of an aiding emulsifying agent. After orally administered, the product automatically becomes emulsion in a gastrointestinal tract. Therefore, the product is called as an automatic emulsifying agent. Because the diameter of a liquid drip of an oil phase is small in the emulsion, a surface area is large. Simultaneously, medicine in the emulsion is easy to absorb by the gastrointestinal tract of a human body due to the emulsifying agent. Blood medicine concentration and medicine absorption degree are higher than those of other oral preparations for orally administering the medicine. Consequently, the present invention greatly improves medicine bioavailability.
Description
Technical field
The invention belongs to pharmaceutical product, the liposoluble constituent that is specifically related to Radix Salviae Miltiorrhizae is the Orally administered composition that active component is made.
Background technology
Radix Salviae Miltiorrhizae is the dry root and rhizome of Labiatae salvia (Salvia miltiorrhiza Bge), its chemical constituent mainly is divided into water soluble ingredient and liposoluble constituent, Radix Salviae Miltiorrhizae mainly contains water soluble ingredient with the extract that water extraction method obtains, with the ethanol extraction more than 60% or use supercritical CO
2Extracting the extract that obtains mainly is liposoluble constituent.The liposoluble constituent of Radix Salviae Miltiorrhizae has good pharmacologically active, rolling up the liposoluble constituent that discloses Radix Salviae Miltiorrhizae in 1 the 213rd page at newly organized Chinese medicinal herbal mainly is meant: Tanshinone I (tanshinoneI), Tanshinone I I A (tanshinone II A), Tanshinone I I B (tanshinone II B), dihydrotanshinone I (dihydrotanshinone I), miltirone (miltirone), cryptotanshinone (cryptotanshinone), iso tanshinone I (isotanshinone I), iso tanshinone II (isotanshinone II), dihydroisotanshinone I (dihydroisotanshinone I), different cryptotanshinone (isocryptotanshinone), hydroxyl tanshinone (hydroxytanshinone IIA), Methyl tanshinoate (methyltanshinone), methylene tanshinquinone (methylenetanshinquinone), neotanshinone A, second, third, fourth (danshenxinkun A, B, C, or their mixture D) etc.In these materials, the 15th edition the 353rd page of new pharmacology mentioned tanshinone, Tanshinone II B, cryptotanshinone, Tanshinone I, Methyl tanshinoate, hydroxyl tanshinone, dihydrotanshinone I etc. and is used to prevent and treat diseases such as myocardial ischemia, arteriosclerosis as the main fat-soluble effective ingredient of salviamiltiorrhizabung, also can be used for treating skin ulcer that staphylococcus aureus causes, carbuncle, cellulitis, acne and other diseases and treats other bacterial infection disease as antimicrobial drug.
The known oral formulations that contains fat soluble ingredient of red sage root has TANSHINONES sheet and tanshinone capsule, and these medicines can not well absorb and utilize at intestines and stomach.At people's (Acta Pharmaceutica Sinicas 1992 such as document " cryptotanshinone and metabolite thereof are at the intravital pharmacokinetic of pig " Xue Ming, 34 (2): 81～84) result of study show gavage the 40mg/kg fat soluble ingredient of red sage root to pig after blood drug level almost nil, illustrate that oral absorption is very poor.Put down in writing the bioavailability that people attempt to improve with certain methods the liposoluble constituent of Radix Salviae Miltiorrhizae, but the limitation that these technology often exist some to be difficult to overcome.If any the people mention the bioavailability that can adopt liposome technology to improve TANSHINONES (" stability of tanshinone liposome and envelop rate research ". Chinese crude drug, 2004,27 (4): 293), but there be stability and the envelop rate problem that is difficult to overcome in this technology, and the technology more complicated.Contemporary Chinese application pharmacy 05 phase of calendar year 2001 discloses a kind of method that the common abrasive method of TANSHINONES-pregelatinized Starch is improved " dissolution of insoluble drug TANSHINONES ", but this method makes the dissolution increase rate of TANSHINONES limited, still can not solve the problem of TANSHINONES oral absorption difference.
Summary of the invention
The objective of the invention is to prepare a kind of new pharmaceutical composition, make the fat soluble ingredient of red sage root in vivo can good absorption, make it better to bring into play its drug action.
To achieve the object of the present invention, the technical scheme that is adopted is to contain the Orally administered composition that fat soluble ingredient of red sage root makes to be made up of following raw materials by weight percent:
Fat soluble ingredient of red sage root 0.3～3%
Oil 20～70%
Emulsifying agent 25～75%
Co-emulsifier 0～20%
This compositions is particularly suitable for making oral formulations, as soft capsule, hard capsule etc.
The commercially available prod of said fat soluble ingredient of red sage root normally Radix Salviae Miltiorrhizae obtains with supercritical carbon dioxide extraction with extraction of the alcoholic solution more than 60% or Radix Salviae Miltiorrhizae.No matter how obtain, the liposoluble constituent of the Radix Salviae Miltiorrhizae of indication of the present invention contains tanshinone and cryptotanshinone weight content sum is not less than 20% (using high effective liquid chromatography for measuring) with employing
The HPLC method is measured the content method of Tanshinone I I A and cryptotanshinone, with reference to one one 394 pages of 2005 editions Chinese Pharmacopoeias.
The oil that the said oil of the present invention adopts medicine to allow can be one or more oily miscellas wherein such as Oleum Glycines, Semen Maydis oil, vegetable oil, Oleum Arachidis hypogaeae semen, Oleum Cocois, olive oil, Oleum Sesami, Oleum helianthi, almond oil, hydrogenated corn oil, Oleum Cocois C8～10 glyceride, glycerol list/dioleic acid ester, Ethyl linoleate, isopropyl myristate.To adopt 2～4 kinds miscella is good.
The emulsifying agent that the said emulsifying agent of the present invention adopts medicine to allow can be anhydrate one or more a blended emulsifier of Span condensation substance, polyoxyethylene fatty acid condensation substance, polyoxyethylene aliphatic alcohol condensation substance, polyoxyethylene fatty oil condensation substance, poloxalkol of fatty acid glyceride, polyglyceryl fatty acid ester, sucrose fatty acid ester, the Span that anhydrates, polyoxyethylene.To adopt 2～4 kinds blended emulsifier is good.
More than these emulsifying agents specifically can be:
Fatty acid glyceride: as glyceryl monostearate, glyceryl monolaurate etc.;
Polyglyceryl fatty acid ester: as polyglycereol stearate, polyglycerol acrylate, polyglycereol laurate etc.;
Sucrose fatty acid ester: as sucrose monostearate, sucrose palmitic acid ester etc.;
Span anhydrates: spans (spans).
The polyoxyethylene Span condensation substance that anhydrates: Tweens (Tweens);
Polyoxyethylene fatty acid condensation substance: Myrij class (Myrjs);
Polyoxyethylene aliphatic alcohol condensation substance: brejs (Myrjs), peregal 0 ~ 20, polyoxyethylene nonylphenol ether;
Polyoxyethylene fatty oil condensation substance: polyoxyethylene castor oil Cremophor EL, polyoxyethylene hydrogenated Oleum Ricini Cremophor RH etc.
Poloxalkol: pluoronics (Pluronics).
The commercially available prod of below mentioning is particularly useful for the preparation of the present composition.
Single, two, three oleic acid (C18:1, refer to contain 18 carbon atoms and a two key, below roughly the same) glyceride and list, two oleic acid Polyethylene Glycol ester admixtures, it is the product of Labrafil M1944CS that trade name is for example arranged, single, two, three linoleic acids (C18:2) glyceride and list, dilinoleic acid Polyethylene Glycol ester admixture, it is the product of Labrafil M2125CS that trade name is for example arranged, single, two, three sufferings/capric acid (C8-C10) glyceride and list, two sufferings/capric acid Polyethylene Glycol ester admixture, it is the product of Labrasol that trade name is for example arranged, Oleum Cocois C8/C10 carboxylic acid polyethyleneglycol glyceride, it is the product of Labrafac CM10 that trade name is for example arranged, single, two, three lauric acids (C12) glyceride and list, dilaurate Polyethylene Glycol ester admixture, it is the product of Gelucire 44/14 that trade name is for example arranged, single, two, three Palmic acids-stearic acid (C16-C18) glyceride and list, two Palmic acids-stearic acid Polyethylene Glycol ester admixture, it is the product of Gelucire50/13 that trade name is for example arranged, the mono laurate macrogol ester, it is the product of Lauroglycol 90 that trade name is for example arranged;
The polyglycereol stearate, polyglycerol acrylate, polyglycereol laurate;
The oleic acid sorbitan esters, for example name of product is Arlacel 80;
Two oleic acid ethylene oxidic esters-6, for example name of product is Plurol Oleique CC497;
Glyceryl monooleate: propylene glycol (90: 10), for example name of product is Arlacel 186;
Single, double Oleum Cocois C8/C10 short and long-chain acyl triglyceride molecules, for example name of product is Capmul MCM; Three Oleum Cocois C8/C10 short and long-chain acyl triglyceride molecules, for example product is Captex 355; Miglyol 812; Glyceryl linoleate, for example name of product is Myverol;
Two Oleum Cocois C8/C10 carboxylic acid propylene glycol esters, for example name of product is Captex 200;
Acetyl monoglyceride, for example commodity Myvacet;
The oleic acid polyoxyethylene sorbitan esters, Tween 80 etc.;
Three ricinoleic acid polyoxyethylene glycerides, for example name of product is Cremophor EL35;
Three oleic acid polyoxyethylene (25) glyceride, for example name of product Tagat T0;
The preparation method of Orally administered composition of the present invention can be fat soluble ingredient of red sage root, oil and emulsifying agent etc. to be mixed by certain mode get final product.These compositionss can be in water or in the gastrointestinal tract body fluid emulsion of the less oil phase particle diameter of spontaneous formation, can significantly improve the absorption and the bioavailability of medicine.
Prove with the bioavailability test below.
Test specimen: fat soluble ingredient of red sage root capsule (sample 1): (measure by above-mentioned HPLC method with commercially available fat soluble ingredient of red sage root 1 with the acquisition of supercritical carbon dioxide extraction method, the weight content that wherein contains tanshinone is 50%, the weight content of cryptotanshinone is 20%) be the active matter raw material, make self-emulsifying composition by the embodiment of the invention 6, and further be prepared into oral self-emulsifying soft capsule, specification 5.0mg/ grain (calculating with tanshinone and cryptotanshinone) is sample 1.
Radix Salviae Miltiorrhizae extract conventional capsule (sample 2): with fat soluble ingredient of red sage root 1 be crushed to powder granularity less than 40 μ m after with vertical compression lactose mix homogeneously, the hard capsule of packing into No. 1 promptly gets sample 2.Content of dispersion is calculated as the 10.0mg/ grain to contain tanshinone and cryptotanshinone.
Test method: get 6 of Beagle male dogs, be divided into two groups at random.According to dosage 5mg.kg-1 gives 10 of the oral self-emulsifying soft capsules of above dog (sample 1), 5 of fat soluble ingredient of red sage root thing conventional capsules (sample 2) respectively.Before administration and after the administration 0,0.16,0.25,0.50,0.75,1,1.5,2,4,6,9,12,24h gets blood 3ml from femoral vein, anticoagulant heparin leaves standstill, centrifugal (3000rpm) separates, and gets blood plasma; Preserve in-20 ℃ of refrigerators, to be detected.After getting blood at every turn and finishing dog is put in and is free state in the cage.
Measure the tanshinone content in the blood plasma, and calculate relative bioavailability, the results are shown in shown in the following table:
| Test group | C max (μg/mL) | T max(h) | AUC (mg.h.L-1) | Relative bioavailability F (%) |
| Sample 1 | 0.2938 | 1.49 | 1.8985 | 523 |
| Sample 2 | 0.043 | 1.98 | 0.3630 | 100 |
Annotate:
Last table data declaration, the blood drug level of the soft capsule that the oral compositions provided by the present invention of animal is made and relative bioavailability are all made existing oral capsule with the fat soluble ingredient of red sage root of same amount and are exceeded about 4 times.
The invention has the beneficial effects as follows: preparation method is simple; Product can become a kind of emulsion in oral back automatically at gastrointestinal tract.So product of the present invention can be described as self-emulsifier again, because the liquid-drop diameter of oil phase is very little in the emulsion, thereby surface area is very big, simultaneously also because the existence of emulsifying agent is easy to by the gastrointestinal absorption of human body the medicine in the emulsion, the trap of its blood drug level and medicine exceeds much than other oral formulations of oral these medicines, thereby has improved bioavailability of medicament greatly.
Further illustrate technical scheme of the present invention below by embodiment.
The specific embodiment
Embodiment 1
Fat soluble ingredient of red sage root 1 (commercially available): with the Radix Salviae Miltiorrhizae is raw material, obtains with the supercritical carbon dioxide extraction method.Measure by above-mentioned HPLC method, the weight content that wherein contains Tanshinone I I A is 50%, and the weight content of cryptotanshinone is 20%.
Compositions is formed table:
| Material name | Weight (gram) | Percentage by weight % | The composition effect |
| Fat soluble ingredient of red sage root 1 | 10 grams | 1.0 | Active substance |
| Oleum Cocois medium chain length fatty acid triglyceride (MCT) | 630 grams | 63.6 | Oil |
| Tween 80 | 85 grams | 8.6 | Emulsifying agent |
| Single, double, three sufferings/capric acid (C8-C10) glyceride and single, double suffering/capric acid Polyethylene Glycol ester admixture (trade name: Labrasol) | 266 grams | 26.8 | Emulsifying agent |
| Amount to | 991 grams | 100.0 |
Preparation method: by the Oleum Cocois medium chain length fatty acid triglyceride, Tween 80 of material quantity in the table, single, double, three sufferings/capric acid (C8-C10) glyceride and single, double suffering/capric acid macrogol ester etc. with the vortex mixer mixing that vibrates.Other gets fat soluble ingredient of red sage root 1 and is added in the above-mentioned mixed liquor, reuse vortex mixer vibration mix homogeneously, and 40 ℃ of heating in water bath made its principal agent fully dissolve in 10 minutes.Put and be chilled to room temperature, filter, promptly.With the HPLC method measure this self-emulsifying composition sample contain active substance be 6.6mg/ml (with contain tanshinone and cryptotanshinone sum the metering).
Embodiment 2
Compositions is formed table:
| Material name | Weight (gram) | Percentage by weight % | The composition effect |
| Fat soluble ingredient of red sage root 1 | 10 grams | 1.7 | Active substance |
| Isopropyl myristate | 168 grams | 28.7 | Oil |
| Polyoxyethylene hydrogenated Oleum Ricini Cremophor RH-40 | 246 grams | 42.0 | Emulsifying agent |
| Mono laurate macrogol ester (Lauroglycol 90) | 96 grams | 16.4 | Emulsifying agent |
| Tween 80 | 66 grams | 11.3 | Emulsifying agent |
| Amount to | 586 grams | 100.0 |
Operation: add listed emulsifying agent, oil in the table successively, adopt the vortex mixer vibration, make its mix homogeneously.Add fat soluble ingredient of red sage root, reuse vortex mixer vibration mix homogeneously heats in 40 ℃ of water-baths, and principal agent is fully dissolved.Put and be chilled to room temperature, filter, discard residue, filtrate promptly.
With the HPLC method measure this self-emulsifying composition sample contain activity concentration be 10.7mg/ml (with contain tanshinone and cryptotanshinone the metering),
Get this product be added to the water (according to compositions: water=1: 100 weight ratio), with the vortex mixer mix homogeneously that vibrates, the weak reddish violet translucent liquid of talking.Get this liquid and detect the oil phase particle diameter.
Testing result: sample thief records the sample particle diameter between 0.3 μ m～10 μ m with Malvern laser particle size determination instrument, and particle diameter mainly concentrates between 2 μ m～3 μ m and (accounts for distribution of particles ratio about 55%).
Embodiment 3
Fat soluble ingredient of red sage root 2 is to be raw material with Radix Salviae Miltiorrhizae, and the alcoholic solution with 90% extracts the Radix Salviae Miltiorrhizae liposoluble extract that obtains, and measures by above-mentioned HPLC method, and the weight content that wherein contains tanshinone is 18%, and the weight content of cryptotanshinone is 7%.
Compositions is formed table:
| Material name | Weight (gram) | Percentage by weight % | The composition effect |
| Fat soluble ingredient of red sage root 2 | 10 | 1.5 | Active substance |
| Hydrogenated corn oil | 196 | 30.3 | Oil |
| Three ricinoleic acid polyoxyethylene glycerides (Cremophor EL 35) | 196 | 30.3 | Emulsifying agent |
| Ethanol | 98 | 15.1 | Co-emulsifier |
| Oleum Cocois C8/C10 carboxylic acid polyethyleneglycol glyceride (Labrafac CM10) | 147 | 22.7 | Emulsifying agent |
| Amount to | 647 | 100.0 |
Operation:
Listed emulsifying agent, oil, ethanol in the last table are vibrated with vortex mixer, make it be mixed and made into uniform oil-based liquid.Get fat soluble ingredient of red sage root 2, be added in the above-mentioned oil-based liquid, reuse vortex mixer vibration mixes, and 40 ℃ of heating in water bath 20 minutes, principal agent is fully dissolved.Cooling back solution becomes the peony transparence, filters with 0.45 μ m filter membrane, gets subsequent filtrate and promptly is.Containing fat soluble ingredient of red sage root (calculating to contain tanshinone and cryptotanshinone) through HPLC method test sample is 3.5mg/ml.
Embodiment 4
Compositions is formed table:
| Material name | Weight (gram) | Percentage by weight % | The composition effect |
| Fat soluble ingredient of red sage root 2 | 10 | 3.0 | Active substance |
| Olive oil | 35 | 10.4 | Oil |
| Sucrose monolaurate | 140 | 41.7 | Emulsifying agent |
| Polysorbate85 | 20 | 5.7 | Emulsifying agent |
| The single, double oleate of glycerol | 105 | 31.3 | Oil |
| Span 20 (span 20) | 26 | 7.7 | Emulsifying agent |
| Amount to | 336 | 100.0 |
Operation: listed emulsifying agent, oil, ethanol in the last table are vibrated with vortex mixer, make it be mixed and made into uniform oil-based liquid.Fat soluble ingredient of red sage root 2 is added in the above-mentioned oil-based liquid, and reuse vortex mixer vibration mixes, and 40 ℃ of heating in water bath 20 minutes, principal agent is fully dissolved.Cooling back solution becomes the peony transparence, filters with 0.45 μ m filter membrane, gets subsequent filtrate and promptly is.Containing fat soluble ingredient of red sage root (calculating to contain Tanshinone I I A and cryptotanshinone) through HPLC method test sample is 6.9mg/ml.
Aforesaid liquid 1ml is dropped to 37 ℃ gradually, in the 1000ml DDW under 50 rev/mins of stirrings.Dropwise, continue to stir about 10 minutes.Sample thief distributes between 0.3 μ m-10 μ m with the particle diameter of Malvern laser particle size determination instrument working sample, with distribute about 3 μ m more (accounting for distribution of particles ratio 61%).
Embodiment 5
Compositions is formed table:
| Material name | Weight (gram) | Percentage by weight % | The composition effect |
| Fat soluble ingredient of red sage root 1 | 4 grams | 0.3 | Active substance |
| Single, double, three oleic acid (C18:1) glyceride and single, double oleic acid Polyethylene Glycol ester admixture (Labrafil M1944CS) | 210 grams | 16.4 | Emulsifying agent |
| Isopropyl alcohol | 55 grams | 4.3 | Co-emulsifier |
| PEG400 | 102 grams | 8.0 | Co-emulsifier |
| Oleum Arachidis hypogaeae semen | 150 grams | 11.7 | Oil |
| Isopropyl myristate | 200 grams | 15.7 | Oil |
| Polysorbas20 | 102 grams | 8.0 | Emulsifying agent |
| Single, double Oleum Cocois C8/C10 short and long-chain acyl triglyceride molecules (Capmul MCM) | 182 grams | 14.3 | Emulsifying agent |
| Tween 80 | 50 grams | 3.9 | Emulsifying agent |
| Propylene glycol | 72 grams | 5.6 | Co-emulsifier |
| Three oleic acid polyoxyethylene (25) glyceride (Tagat T0) | 150 grams | 11.7 | Emulsifying agent |
| Amount to | 1277 | 100.0 |
Operation: fat soluble ingredient of red sage root is joined in the mixture of listed emulsifying agent of table and oil, adopt the vortex mixer vibration, make its mix homogeneously.In 40 ℃ of water-baths, be heated to and become clear and bright shape.Containing fat soluble ingredient of red sage root (calculating to contain Tanshinone I I A and cryptotanshinone) through HPLC method test sample is 0.7mg/ml.
Get the 1ml aforesaid liquid and drop to 37 ℃ gradually, in the 1000ml DDW under 50 rev/mins of stirrings.Dropwise, continue to stir about 10 minutes.Sample thief distributes between 0.1 μ m-10 μ m with the particle diameter of Malvern laser particle size determination instrument working sample, with distribute about 0.2 μ m more (accounting for distribution of particles ratio 53%).
Embodiment 6
Compositions is formed table:
| Material name | Weight (gram) | Percentage by weight % | The composition effect |
| Fat soluble ingredient of red sage root 1 | 10 | 1.3 | Active substance |
| Single, double, three sufferings/capric acid (C8-C10) glyceride and single, double suffering/capric acid Polyethylene Glycol ester admixture (Labrasol) | 63 | 8.3 | Emulsifying agent |
| Three ricinoleic acid polyoxyethylene glycerides (Cremophor EL35) | 256 | 33.8 | Emulsifying agent |
| Oleum Cocois medium chain length fatty acid triglyceride (MCT) | 290 | 38.3 | Oil |
| Tween 80 | 26 | 3.4 | Emulsifying agent |
| Carbiphene (diethylene glycol monoethyl ether, Transcutol P) | 113 | 14.9 | Emulsifying agent |
| Amount to | 758 | 100.0 |
Operation: will go up single, double in the table, three sufferings/capric acid (C8-C10) glyceride and single, double suffering/capric acid Polyethylene Glycol ester admixture (Labrasol), three ricinoleic acid polyoxyethylene glycerides (Cremophor EL35), Oleum Cocois medium chain length fatty acid triglyceride (MCT), Tween 80, carbiphene (Transcutol P) with the vortex mixer mix homogeneously that vibrates.Get fat soluble ingredient of red sage root and be added in the above oily solution, the reuse vortex mixer shakes, and at 40 ℃ of heating in water bath, principal agent is fully dissolved, and is cooled to 20 ℃, 3000 rev/mins centrifugal 10 minutes, getting supernatant is compositions (lower floor's residue discards).
Get above compositions fluid drips and add that (compositions: water=1: 100V/V), the vortex mixer vibration is observed in the distilled water.Has faint lavender opalescence.With the particle diameter of Malvern laser particle size determination instrument working sample oil phase, size is more even, between 0.3 μ m～2 μ m (accounting for distribution of particles ratio 79%).
Getting above self-emulsifying composition liquid detects with the HPLC method, this self-emulsifying composition contains fat soluble ingredient of red sage root 8.8mg/ml (calculating to contain tanshinone and cryptotanshinone), contain active matter 5.0mg (every about 0.63ml compositions of loading amount) loading amount by every, make soft capsule, be called the fat soluble ingredient of red sage root self-emulsifying soft capsule.
The self-emulsifying ability test: get the soft capsule of above preparation, adopt 2000 editions two dissolution determination devices of Chinese Pharmacopoeia, 1000ml distilled water (including 1% Tween 80) is a medium, 37 ℃, and the slurry method, 100 rev/mins are carried out the dissolution test.Take a sample respectively at 10 minutes, 15 minutes, 30 minutes time points, with the particle diameter of Malvern laser particle size determination instrument working sample, size is more even, all between 0.3 μ m-2 μ m.Measure dissolution with the HPLC method, each sample point dissolution is respectively 95%, 98%, 97% of labelled amount as a result.
Claims (4)
1. one kind contains the Orally administered composition that fat soluble ingredient of red sage root is made, and it is characterized in that, said Orally administered composition is made up of following raw materials by weight percent:
Fat soluble ingredient of red sage root 0.3～3%
Oil 20～70%
Emulsifying agent 25～75%
Co-emulsifier 0～20%
Said emulsifying agent is anhydrate one or more a blended emulsifier of Span condensation substance, polyoxyethylene fatty acid condensation substance, polyoxyethylene aliphatic alcohol condensation substance, polyoxyethylene fatty oil condensation substance, poloxalkol of fatty acid glyceride, polyglyceryl fatty acid ester, sucrose fatty acid ester, the Span that anhydrates, polyoxyethylene.
2. according to the said Orally administered composition of claim 1, it is characterized in that tanshinone and cryptotanshinone weight content sum are not less than 20% in the liposoluble constituent of said Radix Salviae Miltiorrhizae.
3. according to the said Orally administered composition of claim 1, it is characterized in that said oil is one or more oily miscellas wherein such as Oleum Glycines, Semen Maydis oil, hydrogenated corn oil, vegetable oil, Oleum Arachidis hypogaeae semen, Oleum Cocois, olive oil, Oleum Sesami, Oleum helianthi, almond oil, Oleum Cocois C8～10 glyceride, glycerol list/dioleic acid ester, Ethyl linoleate, isopropyl myristate.
4. according to the said oral formulations of claim 1, it is characterized in that said co-emulsifier is ethanol or propylene glycol, PEG400, isopropyl alcohol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100364831A CN100435783C (en) | 2005-08-12 | 2005-08-12 | Orally administered composition containing fat soluble ingredient of red sage root |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100364831A CN100435783C (en) | 2005-08-12 | 2005-08-12 | Orally administered composition containing fat soluble ingredient of red sage root |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1736412A CN1736412A (en) | 2006-02-22 |
| CN100435783C true CN100435783C (en) | 2008-11-26 |
Family
ID=36079484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100364831A Expired - Fee Related CN100435783C (en) | 2005-08-12 | 2005-08-12 | Orally administered composition containing fat soluble ingredient of red sage root |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100435783C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080047956A (en) * | 2006-11-27 | 2008-05-30 | 주식회사 엠디바이오알파 | Pharmaceutical composition for treatment and prevention of diseases involving impotence |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1227109A (en) * | 1998-02-27 | 1999-09-01 | 烟台大学 | Medicine for curing atherosclerosis |
-
2005
- 2005-08-12 CN CNB2005100364831A patent/CN100435783C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1227109A (en) * | 1998-02-27 | 1999-09-01 | 烟台大学 | Medicine for curing atherosclerosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1736412A (en) | 2006-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3391961B2 (en) | Cyclosporin-containing soft capsule composition | |
| CN110035774A (en) | Cannboid dilutes preparation and preparation method thereof | |
| CN100367930C (en) | Spontaneously dispersible N-benzoyl staurosporine compositions | |
| EP2062571B1 (en) | Self-emulsifying pharmaceutical composition with enhanced bioavailability | |
| CN101862306A (en) | New type slightly soluble oral medicine self-emulsification preparation and preparation method thereof | |
| TW200422057A (en) | Composition in form of emulsion or microemulsion pre-concentrate for oral administration and its uses | |
| CA2432362A1 (en) | Micellar colloidal pharmaceutical compositions containing a lipophilic active principle | |
| EP1249230B1 (en) | Microemulsion-preconcentrates and microemulsions comprising coenzyme Q10 | |
| AU2007333355B2 (en) | Microemulsion dosage forms of valsartan and methods of making the same | |
| CN100463669C (en) | Self-emulsifying agent of compound artemether | |
| CN100506225C (en) | Pharmaceutical use, medicine composition and preparation process of angelica oil components | |
| CN105125489B (en) | Pharmaceutical composition comprising Debiopharm | |
| CN101143142A (en) | Silybin supersaturated self-emulsion composition and preparation method thereof | |
| US20080064760A1 (en) | Spontaneously Dispersible Pharmaceutical Composition | |
| CN100435783C (en) | Orally administered composition containing fat soluble ingredient of red sage root | |
| CN101011373A (en) | Pharmaceutical composition containing L-carnitine and preparation method thereof | |
| CN1810240A (en) | Prepn process and use of total andrographolide emulsion | |
| CN102727793A (en) | Yikunning pharmaceutical composition solid lipid nanosphere preparation | |
| CN1935126A (en) | Artemether self-emulified capsule and its preparing method | |
| CN100536857C (en) | Soft capsule of extractive from leaves of persimmon and self-emulsifying system for releasing drug | |
| CN1457776A (en) | Self emulsified soft capsule of ginkgo leaf extract and its preparing method | |
| KR100524700B1 (en) | Pharmaceutical compositions for Hyperlipidemia treatment using of Self Emulsifying drug delivery system | |
| CN101912447A (en) | Rhizoma corydalis total alkaloids self-emulsifying drug delivery system and preparation method and application thereof | |
| CN101574397B (en) | WuRenChun self-emulsifying soft capsule preparation and preparation method | |
| SI26054A (en) | Super-saturable oil-free self-nanoemulsifying drug delivery system SNEDDS for poorly water-soluble pharmaceutical composition and procedure of preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081126 Termination date: 20120812 |